15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 9 firms covering Legend Biotech Corp, 5 rate it Buy or better, 4 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $24.00 to $78.00 (about 3.3x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $50.11 sits 144% above the current $20.50. The rating mix has stayed broadly stable, with Buy-side ratings easing from 8 to 5 over recent months. On the fundamentals, the Street sees revenue growth near 40% this year and 28% next, consensus EPS building from about $0.09 next quarter toward $0.88 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS9 ratings
Moderate Buy
Strong Buy00%
Buy556%
Hold444%
Sell00%
Strong Sell00%
Based on 9 analysts giving stock ratings to Legend Biotech Corp.
As of Sep, 5 of 9 firms rate LEGN a Buy (4 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
LEGN EPS & revenue forecast
EPS · NEXT QUARTER
$0.09
Range $0.09 – $0.09 · 1 analysts · -156% YoY
Next period, 1 analysts expect Legend Biotech Corp to earn $0.09 a share (range $0.09 – $0.09), versus $-0.16 a year earlier. Full-year consensus is $-0.01, growing to $0.88 the year after.
REVENUE · NEXT QUARTER
$383.0M
Range $357.9M – $399.7M · 1 analysts · +33% YoY
Revenue is expected to reach $383.0M (range $357.9M – $399.7M), +33.0% year-over-year. Full-year consensus is $1.4B, rising to $1.8B next year.
Top analysts covering Legend Biotech Corp
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on LEGN.
#1
Leonid Timashev
RBC Capital · Rank #33
Buy
$58.00+182.9% to target
Overall win rate
48%
+ Follow
#2
Jessica Fye
JP Morgan · Rank #71
Hold
$35.00+70.7% to target
Overall win rate
53%
+ Follow
#3
Mitchell Kapoor
HC Wainwright & Co. · Rank #193
Buy
$65.00+217.1% to target
Overall win rate
34%
+ Follow
#4
George Farmer
Scotiabank · Rank #240
Buy
$76.00+270.7% to target
Overall win rate
44%
+ Follow
#5
Matthew Harrison
Morgan Stanley · Rank #300
Buy
$49.00+139.0% to target
Overall win rate
45%
+ Follow
LEGN stock forecast FAQ
What is LEGN's average 12-month price target?+
The 9 analysts with a live target average $50.11 for Legend Biotech Corp over the next 12 months, ranging from a $78.00 high to a $24.00 low.
Is LEGN stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 9 analyst ratings, 5 are Buy or Strong Buy, 4 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for LEGN?+
The Street-high target is $78.00 (Barclays), and the Street-low is $24.00 (TD Cowen). The average of all 9 active targets is $50.11.
How many Wall Street analysts cover LEGN?+
9 analysts have an active rating on Legend Biotech Corp, and 9 firms carry a live 12-month price target.
Who is the most accurate analyst covering LEGN?+
Among analysts who currently cover LEGN, Leonid Timashev of RBC Capital has the strongest overall Quantellect track record (Rank #33). Their current call is Buy with a $58.00 target.
What is Legend Biotech Corp's projected EPS for next quarter?+
The consensus estimate is $0.09 per share (range $0.09 – $0.09) across 1 analysts. Full-year EPS is projected at $-0.01, rising to $0.88 the following year.
How much revenue is Legend Biotech Corp expected to report next quarter?+
Consensus revenue is $383.0M (range $357.9M – $399.7M). Full-year revenue is projected at $1.4B, growing to $1.8B next year.
Have analysts been upgrading or downgrading LEGN lately?+
As of Sep, 5 of 9 firms rate LEGN a Buy (4 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their LEGN calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
